Guest View
User: Pass: | become a member


CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified

Courtesy of Benzinga.

A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating his opinion that Alkermes’ drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes’ CEO nor the FDA have made any statement indicating if the drug will be approved.


For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.

Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!




You must be logged in to make a comment.
You can sign up for a membership or get a free SWW trial or log in.

Dashboard

 Sector Performances (Today)

 Thermal Imaging